As one of the leading pharma companies in Turkey, DEVA is pioneering a new approach to generics in the country. Chairman of the Board and CEO Philipp Haas discusses the company’s presence and strategy in international markets, how the firm is leveraging its three US FDA-approved and EU GMP-certified production facilities to build a quality-focused image, and how a raft of new investments aims to position DEVA as a local leader. Moreover, Haas explains DEVA’s pandemic journey and its substantial investments in R&D.
[R&D] is the gateway to successful production and competition in the marketplace. Without R&D, DEVA would not be where it is today
